ArticleScientific reports2025
Clinical significance of TAM receptor in the minor salivary glands of patients with Sjögren's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies.Oxford open immunology · 2026Review
- Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sjögren's disease is a chronic autoimmune disorder characterized by lymphocytic infiltration of the salivary and lacrimal glands, often accompanied by systemic manifestations. Dysregulation of immune homeostasis, including impaired clearance of apoptotic cells and aberrant type I interferon (IFN) signaling, plays a key role in its pathogenesis. Tyro3, Axl, and Mer tyrosine kinase (MerTK)-collectively known as TAM receptors-regulate efferocytosis and dampen IFN-mediated inflammation. While deficiencies in TAM signaling have been implicated in various autoimmune diseases, their role in Sjögren's disease remains poorly understood. We evaluated the expression of Tyro3, Axl, and MerTK in minor salivary gland tissues from 74 patients with Sjögren's disease using immunohistochemistry. Associations with clinical and laboratory features, including the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and Damage Index (SSDDI), were analyzed. Among the TAM receptors, MerTK expression was significantly associated with higher focus scores, serum IgG levels, anti-SS-A antibody titers, and increased ESSDAI and SSDDI scores. Tyro3 and Axl expression did not show meaningful correlations with clinical parameters. In conclusion, MerTK expression in minor salivary glands is associated with increased disease activity and immune activation in Sjögren's disease, suggesting its potential role as a tissue biomarker and a modulator of local immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.